meglumine antimonate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1669 133-51-7

Description:

MoleculeDescription

Synonyms:

  • meglumine antimonate
  • glucantime
  • meglumine antimoniate
  • methylglucamine antimonate
ANTIMONY salt of meglumine that is used in the treatment of LEISHMANIASIS.
  • Molecular weight: 365.98
  • Formula: C7H18NO8Sb
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 117.76
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.85 g P

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC P01CB01 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTIPROTOZOALS
AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS
Antimony compounds
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chemotherapy-induced nausea and vomiting indication 236084000
Hepatic failure contraindication 59927004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
CHEMBL239129 ChEMBL_ID
DB13732 DRUGBANK_ID
64953 PUBCHEM_CID
319866 RXNORM
005847 NDDF
714533009 SNOMEDCT_US
D000077485 MESH_DESCRIPTOR_UI
C1096768 UMLSCUI
75G4TW236W UNII

Pharmaceutical products:

None